Comparison Of Different Dosage Of Dexamethasone As Pre-medication In NSCLC Patients With First Line Docetaxel-Platinum-Based Chemotherapy

Background:With the increasing prevalence of cancer and the drastic side effects of its treatment,it is important to search for how to make cancer treatment less hazardous and more effective.The purpose of this study is to compare standard dose of dexamethasone with modified low dose dexamethasone when being given as pre-treatment to the patient who received Docetaxel-Platinum-based chemotherapy and evaluates if modified dosage can still as effectively as standard dosage.Methods:ALL 38 cases were presented between June 2014 to June 2016 in First Affiliated Hospital of Dalian Medical University oncology department and were diagnosed with NSCLC.Patients were divided into 2 groups,all received Docetaxel-Platinum-based chemotherapy.In the second group(B),patients received standard dose dexamethasone pre-treatment,4mg po bid,total 24 mg for 3 days.In the first group(A),patients received modified low dose Dexamethasone pre-treatment,7.5 mg po the night before chemotherapy,5 or 10 mg in 100ml normal saline next day.Results:The Findings of this study revealed that the change in dosage of Dexamethasone pre-treatment showed significant correlation with response,myelosuppression(thrombocytopenia and neutropenia)and gastrointestinal toxicity.The findings of the t-test analysis revealed that Myelosuppression(especially Thrombocytopenia)are significantly high in the first group,Furthermore,the estimated median of progression free survival was 4.26 ± 0.47 months(*p<0.05).The hazard ratio appeared as 0.87± 0.17.This reflects that survival is better in the group those who were given modified dosage of pre-treatment.Conclusion:This study indicated that we prefer modified dosage of Dexamethasone pre-treatment for NSCLC patients who receive Docetaxel-Platinum-based chemotherapy because it shows less hazardous and fewer side effects when it is compared to standard dosage of Dexamethasone pre-treatment.However,how to ensure cancer patients’ health and reduce toxicity,we still need further study and carry on research about this topic.